Shares of Selecta Biosciences Inc (NASDAQ:SELB) have been assigned a consensus recommendation of “Buy” from the eight brokerages that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $31.75.

A number of research analysts have recently commented on SELB shares. BidaskClub raised Selecta Biosciences from a “hold” rating to a “buy” rating in a report on Thursday, September 6th. Canaccord Genuity reaffirmed a “buy” rating and set a $40.00 target price on shares of Selecta Biosciences in a report on Thursday, June 28th. Janney Montgomery Scott began coverage on Selecta Biosciences in a report on Wednesday, June 27th. They set a “buy” rating and a $33.00 target price on the stock. Mizuho reaffirmed a “buy” rating and set a $30.00 target price on shares of Selecta Biosciences in a report on Thursday, August 9th. Finally, Stifel Nicolaus began coverage on Selecta Biosciences in a report on Friday, September 14th. They set a “buy” rating and a $24.00 target price on the stock.

Shares of SELB traded up $0.29 during trading hours on Friday, reaching $14.34. 109,900 shares of the company’s stock traded hands, compared to its average volume of 219,545. The firm has a market capitalization of $317.80 million, a price-to-earnings ratio of -4.52 and a beta of -3.43. The company has a debt-to-equity ratio of 0.87, a quick ratio of 4.96 and a current ratio of 4.96. Selecta Biosciences has a twelve month low of $7.95 and a twelve month high of $24.02.

Selecta Biosciences (NASDAQ:SELB) last issued its quarterly earnings results on Wednesday, August 8th. The company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). Selecta Biosciences had a negative net margin of 31,556.04% and a negative return on equity of 150.84%. analysts forecast that Selecta Biosciences will post -3.13 EPS for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in SELB. BlackRock Inc. grew its holdings in Selecta Biosciences by 40.4% during the second quarter. BlackRock Inc. now owns 884,564 shares of the company’s stock worth $11,721,000 after acquiring an additional 254,586 shares during the period. JPMorgan Chase & Co. grew its holdings in Selecta Biosciences by 40.4% during the first quarter. JPMorgan Chase & Co. now owns 612,422 shares of the company’s stock worth $6,240,000 after acquiring an additional 176,111 shares during the period. Artal Group S.A. acquired a new position in Selecta Biosciences during the first quarter worth about $1,274,000. Millennium Management LLC acquired a new position in Selecta Biosciences during the second quarter worth about $1,583,000. Finally, Proxima Capital Management LLC acquired a new position in Selecta Biosciences during the second quarter worth about $1,075,000. 48.75% of the stock is currently owned by hedge funds and other institutional investors.

Selecta Biosciences Company Profile

Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.

Read More: Fundamental Analysis – How It Helps Investors

Analyst Recommendations for Selecta Biosciences (NASDAQ:SELB)

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.